Early Onset of Efficacy Using a 1% and 2% Topical Minocycline Gel for the Treatment of Rosacea: a Small Open Label Study

N Bhatia; M Ahmadyar; H Hansra; J Del Rosso; H Baldwin; AM Daniels

doi:10.25251/skin.2.supp.34

N Bhatia
M Ahmadyar
H Hansra
J Del Rosso
H Baldwin
AM Daniels

Keywords

minocycline, rosacea

Abstract

Abstract not available.

Disclosures: Study supported by BioPharmX, Inc.

Poster PDF

Published

Feb 23, 2018

DOI https://doi.org/10.25251/skin.2.supp.34

How to Cite

Bhatia, N., Ahmadyar, M., Hansra, H., Del Rosso, J., Baldwin, H., & Daniels, A. (2018). Early Onset of Efficacy Using a 1% and 2% Topical Minocycline Gel for the Treatment of Rosacea: a Small Open Label Study. SKIN The Journal of Cutaneous Medicine, 2(S1), S35. https://doi.org/10.25251/skin.2.supp.34

Issue

Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii

Section

Rosacea

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

Ulrich Mrowietz, Tal Hetzroni Kedem, Rita Kenyan, Meir Eini, Dov Tamarkin, Mitchell Shirvan, Topical Minocycline Foam (FMX-103) for the Treatment of Moderate-to-Severe Rosacea: Results of a Phase 2, Randomized, Double-Blind, Multicenter Clinical Study , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Linda Stein Gold, Joshua Zeichner, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi, DFD 29, a low dose oral minocycline, shows significant improvement in quality of life in subjects with papulopustular rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Dr. Srinivas Sidgiddi, Aniruddh Gautam, MPharm, Comparative Bioavailability of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) Vs. Minocycline Hydrochloride Extended Release 105-mg tablets After a Single Oral Dose: A Randomized, 3-way Crossover Study , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Athanasios Tsianakas, Neal Bhatia, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi, DFD-29, a low dose oral minocycline, demonstrates superior efficacy as compared to placebo and Oraycea ® Capsules (doxycycline HCl) in subjects with papulopustular rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Linda Stein Gold, James Q Del Rosso, Neal D Bhatia, et al., Efficacy and Safety of FMX103 (1.5% Minocycline Foam) in the Treatment of Moderate to Severe Papulopustular Rosacea: Results from two Phase 3 Randomized, Multicenter, Double Blind, Vehicle Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
Terry Jones, Iain Stuart, Pharmacokinetics of Minocycline Foam FMX103 in Subjects With Moderate-to-Severe Facial Papulopustular Rosacea Under Maximum-Use Conditions: Results of a Phase 1 Study , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
James Q Del Rosso, Linda Stein Gold, Leon Kircik, Neal Bhatia, Neil Sadick, Matthew Zirwas, Edward Lain, Iain Stuart, Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, James Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart, Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
James Q Del Rosso, Linda Stein Gold, Leon Kircik, Neal D Bhatia, Neil Sadick, Matthew Zirwas, Edward Lain, Iain Stuart, Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Linda Stein Gold, James Q Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart, Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)

You may also start an advanced similarity search for this article.

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)